Skip to content

Bain Capital Specialty Finance BCSF Deferred offering costs

Deferred offering costs at other companies

Oaktree Specialty Lending logo
Oaktree Specialty LendingOCSL
$43K-73.3%

Other financials

Income statement

See full
Net income$3.4M-88.1%
EPS (diluted)$0.05-88.6%

Balance sheet

See full
Cash & equivalents$13.0M+27.6%
Total debt$1.8B+0.2%
Total equity$1.1B-4.5%
Total assets$2.6B-1.5%

Cash flow

See full
Operating cash flow$26.6M+466%

Valuation

See full
Market cap$781.02M-19.3%
Enterprise value$2.52B-6.9%
P/E10.6×+2.0×

Returns & leverage

See full
Return on equity6.6%-3.3pp
Debt / equity1.6×+0.1×

Where this comes from

Reported directly by Bain Capital Specialty Finance in its filing.

Tagged under the XBRL concept us-gaap:DeferredOfferingCosts.

The official record: Bain Capital Specialty Finance’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Bain Capital Specialty Finance's deferred offering costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Bain Capital Specialty Finance's deferred offering costs?
Bain Capital Specialty Finance (BCSF) reported deferred offering costs of $3.29M in Q1 2026.
How has Bain Capital Specialty Finance's deferred offering costs changed year-over-year?
Bain Capital Specialty Finance's deferred offering costs decreased by 24.2% year-over-year, from $4.33M to $3.29M.
What is the long-term trend for Bain Capital Specialty Finance's deferred offering costs?
Over 4 years (2021 to 2025), Bain Capital Specialty Finance's deferred offering costs has grown at a 12.9% compound annual growth rate (CAGR), from $2.18M to $3.54M.
What does deferred offering costs mean?
These are costs directly attributable to the issuance of equity or debt securities that are capitalized and amortized over the life of the instrument. This metric reflects the upfront investment required to raise capital for investment operations. Tracking these costs helps in understanding the efficiency of the company's capital raising activities.